Lund, Sweden — August 28, 2025 — The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Oczyesa®, a once-monthly subcutaneous octreotide depot, as maintenance treatment for adults with acromegaly who have responded to and tolerated somatostatin analog therapy.
Science Significance
Acromegaly, a rare endocrine disorder, results from excess growth hormone and insulin-like growth factor-1 (IGF-1) production, often due to pituitary tumors. Left untreated, it leads to abnormal growth of bones, enlarged organs, and reduced quality of life. Clinical studies, including the Phase 3 ACROINNOVA program, demonstrated that Oczyesa provides sustained biochemical control and symptom relief with convenient once-monthly dosing. This represents a significant advance over traditional intramuscular therapies.
Regulatory Significance
The MHRA’s marketing authorization follows a prior European Commission approval in June 2025, reinforcing Oczyesa’s regulatory momentum. Based on a comprehensive clinical package of seven trials, this approval reflects regulators’ recognition of its higher bioavailability and patient-friendly delivery system. The ruling marks an important step in broadening access to innovative endocrine therapies in Europe.
Business Significance
Advertisement
The treatment of acromegaly, though a rare disease, represents a niche but high-value biopharmaceutical market. By addressing unmet needs through simplified administration and improved patient adherence, Oczyesa strengthens the competitive landscape in endocrine care. Approval in the UK sets the stage for expansion into additional European and global markets, opening pathways for broader commercial adoption.
Patients’ Significance
For patients, the impact is profound: self-administration with an autoinjector pen, reduced clinic visits, and greater autonomy in managing a lifelong condition. The once-monthly regimen is designed to improve quality of life, treatment satisfaction, and long-term adherence, while reducing the burden of frequent hospital-based injections.
Policy Significance
The decision aligns with healthcare policies aimed at empowering patients through self-care, improving access to therapies for rare diseases, and reducing system-wide costs. With acromegaly prevalence estimated at 60 cases per million, policy frameworks supporting early diagnosis and sustained management will be essential for optimizing outcomes with such novel therapies.
The approval of Oczyesa in the UK marks a turning point in acromegaly care, combining scientific innovation, regulatory support, and patient empowerment. As additional launches roll out across Europe, this once-monthly treatment may establish a new standard of care for endocrine disorders, advancing precision and convenience in chronic disease management.
Source: Camurus Press Release
